You may recall the ridiculous and dangerous bias that drugmakers show toward their own useless and toxic concoctions in the studies they fund. The very same thing is true for breast cancer treatment trials, according to a new report.
Again, the numbers tell the real story here, based on a review of 140 studies published in 1993 (45), 1998 (39) and 2003 (56) and culled from 10 medical journals:
One more interesting factoid worth noting that tells you all you need to know about how damning this study really is: Three of the four researchers who worked on it do consulting for drug companies, including Merck, AstraZeneca and GlaxoSmithKline.